Top 5 Blue Chip Stocks To Own Right Now

Sports and stocks go hand in hand.

Wall Street denizens often talk about slam dunk investments and describe the economic cycle as being in a particular inning.

So it makes perfect sense that there’s an ETF dedicated to the business of sports.

The ProSports Sponsors exchange-traded fund, which has the ticker symbol FANZ (FANZ), invests in companies that have business deals with the four major US team sports leagues.

Nick Fullerton, CEO of SportsETFs, the company behind the fund, said it was set up last year to take advantage of the popularity of team sports, which bring in big dollars.

Legal gambling, which is set to spread across the United States, could boost that popularity even more.

Fullerton was quick to point out that the companies in the FANZ ETF must have an actual sponsorship with a major league, and not just a naming rights deal on a stadium.

No CMGIs or Enrons here.

“These are blue chip companies with strong balance sheets and cash flow,” Fullerton said.

Top 5 Blue Chip Stocks To Own Right Now: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Vermillion (NASDAQ: VRML) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

  • [By Logan Wallace]

    Vermillion, Inc. (NASDAQ:VRML) CFO Robert Harry Beechey bought 100,000 shares of Vermillion stock in a transaction dated Tuesday, August 14th. The stock was acquired at an average cost of $0.52 per share, for a total transaction of $52,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

  • [By Benzinga News Desk]

    Shari Redstone is one “disloyal” media heiress, according to CBS (NYSE: CBS): Link

    ECONOMIC DATA
    US Initial Jobless Claims for May 18 234.0K vs 220.0K Est; Prior 222.0K. US Continuing Claims for May 11 1.74M vs 1.75M Est; Prior 1.71M
    Existing home sales report for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    Atlanta Fed President Raphael Bostic will speak at 10:35 a.m. ET.
    The Treasury is set to auction 7-year notes at 1:00 p.m. ET.
    The Kansas City Fed manufacturing index for May will be released at 11:00 a.m. ET.
    Philadelphia Federal Reserve Bank President Patrick Harker is set to speak at 2:00 p.m. ET.
    Data on money supply for the latest week will be released at 4:30 p.m. ET.
    ANALYST RATINGS
    UBS upgrades Deere (NYSE: DE) from Neutral to Buy
    Wells Fargo upgrades Oceaneering (NYSE: OII) from Market Perform to Outperform
    Canaccord downgrades Vermillion (NASDAQ: VRML) from Buy to Hold
    Wedbush downgrades Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Max Byerly]

    Vermillion, Inc. (NASDAQ:VRML) CFO Robert Harry Beechey acquired 75,000 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The shares were acquired at an average cost of $0.61 per share, for a total transaction of $45,750.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Stephan Byrd]

    Media headlines about Vermillion (NASDAQ:VRML) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vermillion earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.6924212135165 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Top 5 Blue Chip Stocks To Own Right Now: BWX Technologies, Inc.(BWXT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BWX Technologies (BWXT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BWX Technologies (BWXT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    News coverage about BWX Technologies (NYSE:BWXT) has trended somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BWX Technologies earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 44.8987761555585 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Stephan Byrd]

    Synovus Financial Corp acquired a new stake in shares of BWX Technologies (NYSE:BWXT) during the first quarter, Holdings Channel reports. The fund acquired 1,892 shares of the technology company’s stock, valued at approximately $122,000.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BWX Technologies (BWXT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Blue Chip Stocks To Own Right Now: T-Mobile US, Inc.(TMUS)

Advisors’ Opinion:

  • [By Chris Hill]

    Next up, the Justice Department has formally charged Huawei with a list of crimes that include stealing trade secrets from T-Mobile (NASDAQ:TMUS) as well as bank and wire fraud. And while China will have the telecom and smartphone giant’s back, there’s probably no way this ends well. Finally, after last week’s Brumadinho dam disaster, which spilled 3 million gallons of contaminated mining waste, destroyed a town, and killed at least 65 people in Brazil, Vale (NYSE:VALE) shareholders have to be asking themselves if the company is doomed.

  • [By Daniel B. Kline]

    Give Sprint (NYSE:S) CEO Marcelo Claure credit for stopping the bleeding. His efforts have at least stopped his company’s steady decline in a highly competitive battle with low-price rival T-Mobile (NASDAQ:TMUS), as well as bigger players Verizon (NYSE:VZ) and AT&T (NYSE:T).

  • [By ]

    After years of on-again, off-again talks, Sprint (S) and T-Mobile (TMUS)  finally announced a merger Sunday.

    Sprint investors will receive 0.10256 shares of T-Mobile for each share of Sprint. Based on T-Mobile’s close at $64.52 on Friday, the deal values Sprint at $6.62 per share. Including assumed debt, the deal values Sprint at about $59 billion.

Top 5 Blue Chip Stocks To Own Right Now: Taiwan Semiconductor Manufacturing Company Ltd.(TSM)

Advisors’ Opinion:

  • [By Anders Bylund]

    Cryptocurrency mining is no longer the leading theme in AMD’s analyst reports. Instead, Wall Street’s finest are focusing on AMD’s solid Ryzen and EPYC brands taking market share from Intel (NASDAQ:INTC) in both the server systems and gaming rig markets. On top of AMD’s sharp execution in recent quarters, Intel appears to have fumbled the manufacturing technology lead to the point where AMD can lean on foundry partner Taiwan Semiconductor Manufacturing (NYSE:TSM) to deliver seven-nanometer chip architectures while Intel’s in-house manufacturing lines are stuck at 10 nm.

  • [By Anders Bylund, Chris Neiger, and Ashraf Eassa]

    We asked a handful of your fellow tech investors here at The Motley Fool what they see as the best tech investments in early May. Read on to see why our panelists recommend Taiwan Semiconductor Manufacturing (NYSE:TSM), PayPal (NASDAQ:PYPL), and Crown Castle International (NYSE:CCI) at this moment in time.

  • [By Ashraf Eassa]

    Contract chip manufacturing giant Taiwan Semiconductor Manufacturing Company (NYSE:TSM) recently announced that for 2018, it expects to boost its capital expenditure budget to between $11.5 billion and $12 billion, up from a prior range of $10.5 billion to $11 billion. 

  • [By ]

    The capex budget – In January, Intel set a 2018 capital spending budget of $13.5 billion to $14.5 billion, which was easily above 2017 capex of $11.8 billion. Will the budget be tweaked? Last week, Taiwan Semiconductor (TSM) , the world’s biggest chip foundry, upped its 2018 capex budget by $1 billion to a range of $11.5 billion to $12 billion.

  • [By Ashraf Eassa]

    But there are companies similar to Intel — that is, large-cap chip companies that dominate in their respective fields — that I think are worth considering more closely: Broadcom (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company (NYSE:TSM), and Micron (NASDAQ:MU).

  • [By Ashraf Eassa]

    Taiwan Semiconductor Manufacturing Company (NYSE:TSM), or TSMC for short, is one of Apple’s (NASDAQ:AAPL) most important suppliers. The company has manufactured Apple’s A-series chips starting with the A8 and continuing through to today’s A12 Bionic chip and has been the exclusive manufacturer of all but one of those chips — the A9.

Top 5 Blue Chip Stocks To Own Right Now: Prothena Corporation plc(PRTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.43 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

  • [By Chris Lange]

    Prothena Corp. PLC (NASDAQ: PRTA) shares hit a multiyear low on Monday, one not seen since 2013. This came on the heels of news that the company would be discontinuing development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis.

  • [By Brian Feroldi]

    In response to announcing that it is stopping all clinical development of its lead product candidate, Prothena (NASDAQ:PRTA), a clinical-stage biotech focused on neuroscience and orphan diseases, saw its shares fall 69% as of 11 a.m. EDT.

  • [By Jon C. Ogg]

    Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment fails in a drug study. Now it looks as if Prothena Corporation plc (NASDAQ: PRTA) is on the verge of implosion based upon how its stock price reacted.

  • [By Lisa Levin]

    Prothena Corporation plc (NASDAQ: PRTA) shares dropped 68 percent to $11.79 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

Leave a Reply

Your email address will not be published.